Regulatory & Commercialisation

Nicole Dale

Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge

Pharmatica image showing an anatomically accurate human brain with subtle neural activation inspired by functional MRI imaging, representing psychedelic biotech, mental health therapeutics, CNS drug discovery, and AI-enabled pharmaceutical innovation.

Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.

Nicole Dale

Digital Measures in Clinical Trials: FDA vs EMA Pathways

Clinician reviewing digital measures in clinical trials on a tablet, illustrating regulatory acceptance of digital health technologies, digital biomarkers, and FDA and EMA qualification pathways for modern clinical research.

Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.

Nicole Dale

Where Healthcare AI Investment Is Going — And Where It Isn't

Healthcare AI investment visualisation showing an advanced artificial intelligence network connected to pharmaceutical research, molecular data, and digital health systems. The image represents AI investment trends in healthcare, pharmaceutical innovation, biotech intelligence, machine learning in drug discovery, and the future of healthcare technology.

The data is out: Two-thirds of AI healthcare startup investment went to just three domains. Insight into clinical leadership, gender inclusivity, and geographical access reveals a sector building for investability… not clinical need.

Nicole Dale

The AI Bioweapons Risk: We Cannot Afford to Look Away

Abstract visualisation of AI bioweapons risk showing a connected hexagonal network and glowing AI hub, symbolising biosecurity challenges, gene synthesis screening vulnerabilities, biotechnology innovation, and governance in the pharmaceutical industry.

The risk of AI being used to create a bioweapon is a serious concern for pharma biosecurity after researchers found AI-designed toxins can evade DNA screening. Here’s what you need to know about the AI and bioweapons risk.

Shubhangi Dua

AI in Pharma: Hype vs. What Actually Works

Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.

Shubhangi Dua

AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.